Press Announcement Title:

Neo Quantum Era Advances Preclinical Genomic Research Initiative

Neo Quantum Era announces continued development ofZPE-77, an exploratory research platform integrating genomic editing methodologies with engineered nanoparticle delivery systems.The initiative focuses on structured evaluation of
programmable molecular architectures and translational feasibility modeling.ZPE-77 remains investigational and in preclinical research.

March 19, 2025 Orlando Florida Neo Quantum Era, a leader in next generation biomedical innovation, has announced the development of ZPE-77, a cutting edge therapeutic designed to redefine the treatment of gout and metabolic disorders.

Gout affects millions worldwide, yet existing treatments rely on daily medication or repetitive IV infusions that only provide temporary relief. ZPE-77 introduces a revolutionary molecular approach that aims to regulate uric acid levels at their core, reduce inflammation, and promote long-term joint health.

“We believe ZPE-77 represents a paradigm shift in gout treatment,” said Mark Houston Brown, Chief Scientist at Neo Quantum Era. “Rather than just managing symptoms, we are developing a therapy designed to help the body regulate uric acid metabolism more effectively and sustainably.”

A New Approach to Gout Therapy

Unlike conventional treatments that focus on blocking uric acid production or breaking down existing urate crystals, ZPE-77 leverages advanced biotechnology to target the metabolic processes responsible for gout at a molecular level.

Neo Quantum Era Unveils ZPE-77: A Breakthrough in

Gout Treatment